IBAI & Kirkstall14 Oct 2025 10:59
Some notes on Kirkstall (from various tweets direct from kirkstall & other sources)
Quasi Vivo® organ on a chip is a cost effective way to aid research.
It is an in-vitro model, plug‐and‐play, modular design lets you set up advanced 3D cell cultures in minutes.
Metastasis causes 90% of cancer deaths, yet remains incredibly hard to study because lab models can't accurately replicate tumour spread.
Built for Academia & Industry: Academics love the flexibility (run complex 3D cultures without a steep learning curve).
Industry loves the consistency (disposable 6-chamber trays for high-content screens , reproducible results).
One platform, tuned for all users.
Perfusion flow cell culture brings lab experiments closer to real-life conditions.
Ethical, reliable research without animal testing , the recently passed (Dec 22) FDA Modernization Act 2.0 (a bill that authorizes alternatives to animal testing and removes animal studies for biosimilar product ) is aligned with Kirkstall.
92% of drugs that pass animal tests fail in humans.
Big pharma companies testing new drugs can save considerable research costs time /money.
Kirkstall now has more exposure via the groundbreaking team at IBAI with its ever growing eco-system , so i think theres going to be some beneficial synchronity here.
Its a very positive move in my opinion.
Good luck all holders. DYOR
Al.